Molecular testing in routine surgical pathology is becoming an important component of the workup of many different types of tumors. This is especially true for rare types of tumors that are difficult to diagnose and classify using conventional histological and immunohistochemical staining methods. In fact, in some organ systems, such as central nervous system tumors, guidelines now suggest that the standard of care is to obtain specific molecular panels for tumor classification and/or therapeutic management. In addition, in the recently published fifth edition of the WHO Classification of Soft Tissue Tumors, a number of rare mesenchymal tumor entities defined primarily based on genetic characteristics have emerged. In these tumors, molecular genetic approaches play a key role in accurate diagnosis and classification. A comprehensive understanding of the molecular genetic abnormalities unique to these rare tumors is also important for the development of effective targeted therapies in the coming future. At the same time, as the number of potential molecular genetic biomarkers and the associated testing costs continue to increase, pathologists must be able to navigate the molecular testing pathway. Especially in the diagnosis and classification of rare tumors, pathologists need to be able to apply diagnostic molecular tests with high sensitivity and specificity.
As mentioned above, molecular pathology has achieved remarkable success in helping to accurately diagnose, classify tumors, and predict patient outcomes for various cancer types. Our goal is to compile publications focusing on molecular pathology advances in rare and recently characterized tumors in anatomical pathology, as well as on the important role of molecular genetic testing in the diagnosis and classification of these rare tumors.
We welcome submissions on all types of rare tumors in surgical pathology that focus on one or more of the following topics:
• Comprehensive clinicopathological and prognostic studies of rare tumors in surgical pathology
• Novel biomarkers for the accurate diagnosis and classification of difficult-to-diagnose tumors in surgical pathology
• Practical application of fluorescence in-situ hybridization in the diagnosis and classification of rare tumors in surgical pathology
• Application of next-generation sequencing in the diagnosis and classification of rare tumors in surgical pathology
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Molecular testing in routine surgical pathology is becoming an important component of the workup of many different types of tumors. This is especially true for rare types of tumors that are difficult to diagnose and classify using conventional histological and immunohistochemical staining methods. In fact, in some organ systems, such as central nervous system tumors, guidelines now suggest that the standard of care is to obtain specific molecular panels for tumor classification and/or therapeutic management. In addition, in the recently published fifth edition of the WHO Classification of Soft Tissue Tumors, a number of rare mesenchymal tumor entities defined primarily based on genetic characteristics have emerged. In these tumors, molecular genetic approaches play a key role in accurate diagnosis and classification. A comprehensive understanding of the molecular genetic abnormalities unique to these rare tumors is also important for the development of effective targeted therapies in the coming future. At the same time, as the number of potential molecular genetic biomarkers and the associated testing costs continue to increase, pathologists must be able to navigate the molecular testing pathway. Especially in the diagnosis and classification of rare tumors, pathologists need to be able to apply diagnostic molecular tests with high sensitivity and specificity.
As mentioned above, molecular pathology has achieved remarkable success in helping to accurately diagnose, classify tumors, and predict patient outcomes for various cancer types. Our goal is to compile publications focusing on molecular pathology advances in rare and recently characterized tumors in anatomical pathology, as well as on the important role of molecular genetic testing in the diagnosis and classification of these rare tumors.
We welcome submissions on all types of rare tumors in surgical pathology that focus on one or more of the following topics:
• Comprehensive clinicopathological and prognostic studies of rare tumors in surgical pathology
• Novel biomarkers for the accurate diagnosis and classification of difficult-to-diagnose tumors in surgical pathology
• Practical application of fluorescence in-situ hybridization in the diagnosis and classification of rare tumors in surgical pathology
• Application of next-generation sequencing in the diagnosis and classification of rare tumors in surgical pathology
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
